Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer
BJU International · 2025-11 · 136 (5) · 800-804
DOI: 10.1111/bju.16872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJU International, online erschienen am 24.07.2025. Verfasst von Jonathon Carll und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Positron-Emission Tomography, Practice Guidelines as Topic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To provide a comprehensive review and analysis of guidelines from various professional and medical organisations regarding the use of prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) as a staging scan for men with newly diagnosed intermediate‐risk prostate cancer (PCa). Materials and Methods English‐language guidelines and recommendations from the following associations and societies were reviewed and critically analysed: European Association of Urology (EAU), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), Canadian Urological Association (CUA), American Society for Clinical Oncology (ASCO), Society for Nuclear Medicine and Medical Imaging (SNMMI).
Results
There is significant disagreement among guidelines regarding whether PSMA PET is a useful staging tool for men with a new diagnosis of intermediate‐risk PCa. There is a stronger consensus that PSMA PET is useful in staging high‐risk PCa.
Conclusion
Whilst there is a growing body of evidence that supports the use of PSMA PET in newly diagnosed PCa, there is significant disagreement regarding its use for men with intermediate‐risk disease. Recommendations are generally weak and based on expert opinions. This is an area of considerable ongoing research, and guidelines are likely to change as new evidence emerges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Urology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Victoria, Australia.
- Epworth Healthcare, Melbourne, Victoria, Australia.
- Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Surgery, Austin Healthcare, Heidelberg, Victoria, Australia.
ORCID-Profile: Jonathon Carll, Weiwei Shi, Marlon Perera, Nathan Lawrentschuk
Zitieren
APA
Carll, J., Shi, W., Perera, M., Lawrentschuk, N., Chengodu, T., & Woon, D. (2025). Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer. BJU International, 136(5), 800-804. https://doi.org/10.1111/bju.16872
Vancouver
Carll J, Shi W, Perera M, Lawrentschuk N, Chengodu T, Woon D. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer. BJU International. 2025;136(5):800-804. doi:10.1111/bju.16872
BibTeX
@article{Carll2025,
author = {Carll, Jonathon and Shi, Weiwei and Perera, Marlon and Lawrentschuk, Nathan and Chengodu, Thilakavathi and Woon, Dixon},
title = {Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer},
journal = {BJU International},
year = {2025},
volume = {136},
number = {5},
pages = {800--804},
doi = {10.1111/bju.16872}
}
EUVIMED